Qualigen

Qualigen is a biotechnology company that develops and commercializes novel therapeutics for the treatment of cancer and infectious diseases. Read more

CEO Avatar

Chairman & CEO

Michael S. Poirier

CEO Approval Rating

81/100

Founded:

1996

Status:

PublicIndependent CompanyNASDAQQLGN

QUALIGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Evelo Biosciences is the top competitor of Qualigen. Evelo Biosciences is headquartered in Cambridge, Massachusetts, and was founded in 2014. Evelo Biosciences competes in the Biotechnology field. Evelo Biosciences generates 31% the revenue of Qualigen.

Seres Therapeutics is perceived as one of Qualigen's biggest rivals. Seres Therapeutics was founded in Cambridge, Massachusetts} in 2010. Like Qualigen, Seres Therapeutics also operates in the Biotechnology industry. Compared to Qualigen, Seres Therapeutics generates $26M more revenue.

Synlogic is seen as one of Qualigen's top competitors. Synlogic is a Public company that was founded in Cambridge, Massachusetts in 2013. Like Qualigen, Synlogic also works within the Biotechnology industry. Synlogic has 69 more employees vs. Qualigen.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is XOMA a competitor of Qualigen?

Qualigen Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$4.7M

Qualigen's revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 77.9M. Over the last four quarters, Qualigen's revenue has grown by 30.4%. Specifically, in Q1 2021's revenue was $1.9M; in Q3 2020, it was $ < 1M; in Q1 2020, it was $1.6M; in Q1 2020, Qualigen's revenue was $1.5M.

Qualigen Acquisitions

No recent acquisitions found related to Qualigen

Qualigen Funding History

Since Qualigen was founded in 1996, it has participated in 10 rounds of funding. In total Qualigen has raised $63.3M. Qualigen's last funding round was on Dec 2020 for a total of $12.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Dec 2020
$12M
-
Private Placement
Aug 2020
$10M
-
Private Placement
Jul 2020
$8M
-
IPO
Jun 2015
$20M
-
Equity
Dec 2014
$3.7M
-

Since Qualigen was founded in 1996, it has participated in 10 rounds of funding. In total Qualigen has raised $63.3M. Qualigen's last funding round was on Dec 2020 for a total of $12.0M

Qualigen Investments

No recent investments found related to Qualigen

Qualigen News

May 14, 2021BioSpace

Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel thera... See more »
March 1, 2021FinanzNachrichten

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a bi... See more »
January 26, 2021BioSpace

Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack Diagnostics Products in China

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel thera... See more »
December 18, 2020BioSpace

Qualigen Therapeutics, Inc. Announced Closing of $12 Million Registered Direct Offering

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced re... See more »
November 13, 2020MarketScreener

Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results

(marketscreener.com) CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. anno... See more »

Qualigen Blogs

August 13, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board

LOS ANGELES (August 13, 2019) - Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals"... See more »
August 8, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call Market resea... See more »
July 11, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Ritter Shares W... See more »
July 2, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 "Liberatus" Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES (July 2, 2019) - Ritter Pharmace... See more »
July 2, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES&#160;(July 2, 2019) – Ritter Pha... See more »
May 30, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Shares Data from New Study Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Ritter Pharmaceuticals Shares Data from New Study Illuminating the Life Challenges of a Lactose Intol... See more »
May 15, 2019Ritter Pharmaceuticals Blog

Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

LOS ANGELES (May, 14 2019) - Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals" or... See more »

Qualigen Press Releases

July 22, 2020PR Newswire

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates

CARLSBAD, Calif. , July 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen... See more »
July 7, 2020PR Newswire

Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack Rapid Diagnostic System "Which Saved My Life"

CARLSBAD, Calif., July 7, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen"... See more »
April 28, 2020StreetInsider

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the ... See more »
April 25, 2020centralcharts

Ritter Pharmaceuticals, Inc. - RTTR Stock Chart Technical Analysis for 04-24-2020

News videos - Ritter Pharmaceuticals, Inc. - RTTR Stock Chart Technical Analysis for 04-24-2020 - Pub... See more »
January 3, 2020centralcharts

Ritter Pharmaceuticals, Inc. - RTTR Stock Chart Technical Analysis for 01-03-2020

News videos - Ritter Pharmaceuticals, Inc. - RTTR Stock Chart Technical Analysis for 01-03-2020 - Pub... See more »
May 7, 2019StreetInsider

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer ... See more »

Social Media

Qualigen Headquarters

2042 Corte del Nogal Suite B

Carlsbad, California92011

1-760-918-9165

Driving Directions »

Trending Companies

Qualigen Summary

ABOUT

Overview

Qualigen is a biotechnology company that develops and commercializes novel therapeutics for the treatment of cancer and infectious diseases. Qualigen was founded in 1996. Qualigen's headquarters is located in Carlsbad, California, USA 92011. It has ra...

CEO

Qualigen's Chairman & CEO, Michael S. Poirier, currently has an approval rating of 81%. Qualigen's primary competitors are Evelo Biosciences, Seres Therapeutics & Synlogic.

Frequently Asked Questions about Qualigen

  1. When was Qualigen founded?

    Qualigen was founded in 1996
  2. Who is Qualigen's CEO?

    Qualigen's CEO is Michael S. Poirier
  3. How much revenue does Qualigen generate?

    Qualigen generates $4.7M in revenue
  4. How much funding does Qualigen have?

    Qualigen has historically raised $63.3M in funding
  1. Where is Qualigen's headquarters?

    Qualigen's headquarters is in Carlsbad California, USA
  2. How many employees does Qualigen have?

    Qualigen has 7 employees
  3. What sector does Qualigen operate in?

    Qualigen is in Biotechnology, Medical Research & Laboratories
  4. Who are Qualigen's competitors?

    Qualigen's top competitors are Evelo Biosciences, Seres Therapeutics, Synlogic